• Molecules and Cells
• /
• 제26권1호
• /
• pp.100-105
• /
• 2008

Glycogen synthase kinase $3{\beta}$ (GSK $3{\beta}$) is a serine/threonine kinase that phosphorylates substrates such as ${\beta}$-catenin and is involved in a variety of biological processes, including embryonic development, metabolism, tumorigenesis, and cell death. Here, we present evidence that human GSK $3{\beta}$ is associated with Fe65, which has the characteristics of an adaptor protein, possessing a WW domain, and two phosphotyrosine interaction domains, PID1 and PID2. The GSK $3{\beta}$ catalytic domain also contains a putative WW domain binding motif ($^{371}PPLA^{374}$), and we observed, using a pull down approach and co-immunoprecipitation, that it interacts physically with Fe65 via this motif. In addition, we detected co-localization of GSK $3{\beta}$ and Fe65 by confocal microscopy, and this co-localization was disrupted by mutation of the putative WW domain binding motif of GSK $3{\beta}$. Finally, in transient transfection assays interaction of GSK $3{\beta}$ (wt) with Fe65 induced substantial cell apoptosis, whereas interaction with the GSK $3{\beta}$ AALA mutant ($^{371}AALA^{374}$) did not, and we noted that phosphorylation of the Tyr 216 residue of the GSK $3{\beta}$ AALA mutant was significantly reduced compared to that of GSK $3{\beta}$ wild type. Thus, our observations indicate that GSK $3{\beta}$ binds to Fe65 through its $^{371}PPLA^{374}$ motif and that this interaction regulates apoptosis and phosphorylation of Tyr 216 of GSK $3{\beta}$.

• IMMUNE NETWORK
• /
• 제10권3호
• /
• pp.99-103
• /
• 2010

Background: Glycogen synthase kinase $3{\beta}$ ($GSK3{\beta}$) is a ubiquitous serine/threonine kinase that is regulated by serine phosphorylation at 9. Recent studies have reported the beneficial effects of a number of the pharmacological $GSK3{\beta}$ inhibitors in rodent models of septic shock. Since most of the $GSK3{\beta}$ inhibitors are targeted at the ATP-binding site, which is highly conserved among diverse protein kinases, the development of novel non-ATP competitive $GSK3{\beta}$ inhibitors is needed. Methods: Based on the unique phosphorylation motif of $GSK3{\beta}$, we designed and generated a novel class of $GSK3{\beta}$ inhibitor (GSK3i) peptides. In addition, we investigated the effects of a GSK3i peptide on lipopolysaccharide (LPS)-stimulated cytokine production and septic shock. Mice were intraperitoneally injected with GSK3i peptide and monitored over a 7-day period for survival. Results: We first demonstrate its effects on LPS-stimulated pro-inflammatory cytokine production including interleukin (IL)-6 and IL-12p40. LPS-induced IL-6 and IL-12p40 production in macrophages was suppressed when macrophages were treated with the GSKi peptide. Administration of the GSK3i peptide potently suppressed LPS-mediated endotoxin shock. Conclusion: Collectively, we present a rational strategy for the development of a therapeutic GSK3i peptide. This peptide may serve as a novel template for the design of non-ATP competitive GSK3 inhibitors.

• Tuberculosis and Respiratory Diseases
• /
• 제57권5호
• /
• pp.449-460
• /
• 2004

연구배경 : PS-341은 최근에 개발된 강력하고 특이적인 proteasome 억제제로서, 일부 암환자에 투여하여 좋은 성적이 보고되고 있다. Proteasome 억제제의 항암효과는 아포프토시스 유발 물질, 즉 p53, $p21^{WAF/CIP1}$, $p27^{KIP1}$, NF-${\kappa}B$, Bax, Bcl-2 등의 발현 증가와 관련이 있는 것으로 생각되고 있다. JNK와 GSK-$3{\beta}$도 아포프토시스에 관여하는 것으로 잘 알려져 있지만, PS-341에 의한 아포프토시스에서의 역할은 규명되지 못한 상태이다. 본 연구에서는 폐암세포주에서 PS-341에 의한 아포프토시스에서 JNK와 GSK-$3{\beta}$의 역할을 규명하고자 하였다. 방 법 : NCI-H157과 A549 폐암세포주를 실험에 사용하였다. 세포생존능은 MTT 방법으로 평가하였고, 아포프토시스는 PARP의 분해로 평가하였다. JNK의 활성도는 in vitro immuno complex kinase 방법과 내인성 c-Jun의 인산화로 측정하였다. 각종 단백의 발현은 Western 분석으로 평가하였다. JNK1과 GSK-$3{\beta}$의 과발현은 각각 plasmid vector와 adenovirus vector를 이용하였다. 결 과 : PS-341 처치로 아포프토시스에 의한 세포생존율의 감소가 관찰되었다. PS-341 처치로 JNK가 활성화되었고, c-Jun의 발현이 유도되었다. Dominant negative JNK1의 과발현 또는 SP600125 전치치로 JNK의 활성화를 차단하면 PS-341에 의한 아포프토시스가 억제되었다. PS-341 처리로 JNK 활성화에 의존적으로 caspase 3의 활성화가 유도되었다. Caspase 활성화의 차단으로도 PS-341에 의한 아포프토시스가 억제되었다. PS-341에 의해 Akt가 활성화되었고, Akt 활성화의 차단으로 PS-341에 의한 아포프토시스가 심화되었다. PS-341에 의한 Akt 활성화로 GSK-$3{\beta}$가 불활성화되었다. Constitutively active GSK-$3{\beta}$의 과발현으로 PS-341에 의한 아포프토시스가 심화되었고, dominant negative GSK-$3{\beta}$의 과발현으로 PS-341에 의한 아포프토시스가 감소되었다. Lithium chloride 전처치와 dominant negative GSK-$3{\beta}$의 과발현으로 PS-341에 의한 JNK의 활성화와 c-Jun의 발현 증가가 억제되었다. 결 론 : 폐암세포주에서 PS-341에 의한 아포프토시스는 JNK/caspase 경로가 관여하며, 이는 PI3K/Akt 경로를 통한 GSK-$3{\beta}$의 불활성화에 의해 억제되는 것으로 판단된다. 따라서 PS-341의 항암효과를 최대화하기 위해서는 PI3K/Akt 경로를 통한 GSK-$3{\beta}$의 불활성화를 차단하는 치료법이 병행되어야 할 것으로 판단된다.

• Journal of Microbiology and Biotechnology
• /
• 제25권7호
• /
• pp.1170-1176
• /
• 2015

Ginsenosides, the major active component of ginseng, are traditionally used to treat various diseases, including cancer, inflammation, and obesity. Among these, compound K (CK), an intestinal bacterial metabolite of the ginsenosides Rb₁, Rb₂, and Rc from Bacteroides JY-6, is reported to inhibit cancer cell growth by inducing cell-cycle arrest or cell death, including apoptosis and necrosis. However, the precise effect of CK on breast cancer cells remains unclear. MCF-7 cells were treated with CK ($0-70{\mu}M$) for 24 or 48 h. Cell proliferation and death were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry assays, respectively. Changes in downstream signaling molecules involved in cell death, including glycogen synthase kinase $3\beta$ ($GSK3\beta$), $GSK3\beta$, $\beta$-catenin, and cyclin D1, were analyzed by western blot assay. To block $GSK3\beta$ signaling, MCF-7 cells were pretreated with $GSK3\beta$ inhibitors 1 h prior to CK treatment. Cell death and the expression of $\beta$-catenin and cyclin D1 were then examined. CK dose- and time-dependently inhibited MCF-7 cell proliferation. Interestingly, CK induced programmed necrosis, but not apoptosis, via the $GSK3\beta$ signaling pathway in MCF-7 cells. CK inhibited $GSK3\beta$ phosphorylation, thereby suppressing the expression of $\beta$-catenin and cyclin D1. Our results suggest that CK induces programmed necrosis in MCF-7 breast cancer cells via the $GSK3\beta$ signaling pathway.

• 한국자기공명학회논문지
• /
• 제9권1호
• /
• pp.38-47
• /
• 2005

Axin is a scaffold protein of the APC/axin/GSK complex, binding to all of the other signalling components. Axin interacts with Glycogen synthase kinase 3$\beta$ (GSK 3$\beta$) and functions as a negative regulator of Wnt signalling pathways. To determine the solution structure of the GSK3$\beta$ binding regions of the axin, we initiated NMR study of axin fragment comprising residues 3$Val^{388} - Arg^{401}$using circular dichroism (CD) and two-dimensional NMR spectroscopy. The CD spectra of 3$axin^{pep}$ in the presence of 30% TFE displayed a standard 3$\alpha$-helical conformation, exhibiting the bound structure of 3$axin^{pep}$ to GSK3$\bata$. On the basis of experimental restraints including $NOE_s$, and $^3J_{HN\alpha} $ coupling constants, the solution conformation of $axin^{pep}$ was determined with program CNS. The 20 lowest energy structures were selected out of 50 final simulated-annealing structures in both water and TFE environment, respectively. The $RMSD_s$ for the 20 structures in TFE solution were 0.086 nm for backbone atoms and 0.195 nm for all heavy atoms, respectively. The Ramachandran plot indicates that the $\varphi$, $\psi$ angles of the 20 final structures is properly distributed in energetically acceptable regions. $Axin^pep$ in aqueous solutions consists of a stable $\alpha$-helix spanning residues form $Glu^{391}$ to $Val^{391} $, which is an interacting motif with GSK3$\beta$.

• Molecules and Cells
• /
• 제27권1호
• /
• pp.15-19
• /
• 2009

Notch signaling is controlled at multiple levels. In particular, stabilized Notch receptor activation directly affects the transcriptional activations of Notch target genes. Although some progress has been made in terms of defining the regulatory mechanism that alters Notch stability, it has not been determined whether Notch1/NICD stability is regulated by $GSK-3{\alpha}$. Here, we show that Notch1/NICD levels are significantly regulated by $GSK-3{\beta}$ and by $GSK-3{\alpha}$. Treatment with LiCl (a specific GSK-3 inhibitor) or the overexpression of the kinase-inactive forms of $GSK-3{\alpha}/{\beta}$ significantly increased Notch1/NICD levels. Endogenous NICD levels were also increased by either $GSK-3{\alpha}/{\beta}$- or $GSK-3{\alpha}$-specific siRNA. Furthermore, it was found that $GSK-3{\alpha}$ binds to Notch1. Deletion analysis showed that at least three Thr residues in Notch1 (Thr-1851, 2123, and 2125) are critical for its response to LiCl, which increased not only the transcriptional activity of endogenous NICD but also Hes1 mRNA levels. Taken together, our results indicate that $GSK-3{\alpha}$ is a negative regulator of Notch1/NICD.

• Molecules and Cells
• /
• 제37권10호
• /
• pp.747-752
• /
• 2014

Protein kinase C (PKC) family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. However, the role of PKC in receptor activator of NF-${\kappa}B$ ligand (RANKL) signaling has remained elusive. We now demonstrate that $PKC{\beta}$ acts as a positive regulator which inactivates glycogen synthase kinase-$3{\beta}$ (GSK-$3{\beta}$) and promotes NFATc1 induction during RANKL-induced osteoclastogenesis. Among PKCs, $PKC{\beta}$ expression is increased by RANKL. Pharmacological inhibition of $PKC{\beta}$ decreased the formation of osteoclasts which was caused by the inhibition of NFATc1 induction. Importantly, the phosphorylation of GSK-$3{\beta}$ was decreased by $PKC{\beta}$ inhibition. Likewise, down-regulation of $PKC{\beta}$ by RNA interference suppressed osteoclast differentiation, NFATc1 induction, and GSK-$3{\beta}$ phosphorylation. The administration of PKC inhibitor to the RANKL-injected mouse calvaria efficiently protected RANKL-induced bone destruction. Thus, the $PKC{\beta}$ pathway, leading to GSK-$3{\beta}$ inactivation and NFATc1 induction, has a key role in the differentiation of osteoclasts. Our results also provide a further rationale for $PKC{\beta}$'s therapeutic targeting to treat inflammation-related bone diseases.

• Anatomy and Cell Biology
• /
• 제50권3호
• /
• pp.207-213
• /
• 2017

Glycogen synthase kinase $(GSK)-3{\beta}$ and related enzymes are associated with various forms of neuroinflammation, including spinal cord injury (SCI). Our aim was to evaluate whether lithium, a non-selective inhibitor of $GSK-3{\beta}$, ameliorated SCI progression, and also to analyze whether lithium affected the expression levels of two representative $GSK-3{\beta}$-associated molecules, nuclear factor erythroid 2-related factor-2 (Nrf-2) and heme oxygenase-1 (HO-1) (a target gene of Nrf-2). Intraperitoneal lithium chloride (80 mg/kg/day for 3 days) significantly improved locomotor function at 8 days post-injury (DPI); this was maintained until 14 DPI (P<0.05). Western blotting showed significantly increased phosphorylation of $GSK-3{\beta}$ (Ser9), Nrf-2, and the Nrf-2 target HO-1 in the spinal cords of lithium-treated animals. Fewer neuropathological changes (e.g., hemorrhage, inflammatory cell infiltration, and tissue loss) were observed in the spinal cords of the lithium-treated group compared with the vehicle-treated group. Microglial activation (evaluated by measuring the immunoreactivity of ionized calcium-binding protein-1) was also significantly reduced in the lithium-treated group. These findings suggest that $GSK-3{\beta}$ becomes activated after SCI, and that a non-specific enzyme inhibitor, lithium, ameliorates rat SCI by increasing phosphorylation of $GSK-3{\beta}$ and the associated molecules Nrf-2 and HO-1.

• 대한약침학회지
• /
• 제22권4호
• /
• pp.248-252
• /
• 2019

Objectives: The aim of the present work is evaluating the special effects of Urtica Dioica and Lamium Album on the serum level of K-Ras and GSK-3 beta in diabetic rats. Methods: In the present experimental study, 32 male Wistar rats randomly divided into 4 groups (Group I: normal control rats; receiving daily PBS, Group 2: diabetic control rats; receiving single dose of streptozotocin (60 mg/kg) and daily PBS, Group 3: Diabetic rats treated with 100 mg/kg of hydroalcoholic extract of the U. dioica, Group 4: Diabetic rats treated with 100 mg/kg of hydroalcoholic extract of L. Album. Diabetes-induced by an intraperitoneal injection of streptozotocin (60 mg/ kg). On the 14 th day of treatment, the weight, fasting blood sugar (FBS) and on 28 th day blood glucose, K-Ras and GSK3 beta was measured. Results: In diabetic group blood GSK- 3 beta increase in comparison to control group (P < 0.05), also blood K-Ras decrease in the diabetic group (P < 0.05). Both extracts reduced GSK-3 beta level, however, this reduction was only statistically significant by U.dioica (P < 0.05). Compared to diabetic group, blood K-Ras level increased by both extract (P < 0.05). Also diabetes induction increase blood glucose levels and both extracts decrease its level significantly (P < 0.05).there is no significant differences among both extract effects on blood glucose, and K-Ras. Conclusion: For the first time shown that both extracts by regulating GSK-3 beta and K-Ras improve blood glucose level. More studies are needed to determine all the effects of these herbs.

• 한국식품영양과학회지
• /
• 제46권4호
• /
• pp.417-425
• /
• 2017

벌사상자는 여성의 생식기 질환이나 화농성 피부염에 주로 사용되어온 한약재로, 최근 들어 암과 관련된 연구가 많이 이루어짐에 따라 벌사상자의 항암 효과에 대한 관심이 높아지고 있다. 벌사상자의 대표적인 성분인 osthole, xanthotoxol 등은 벤젠고리 화합물로 에탄올과 같은 유기용매에 잘 용해된다. 이에 따라 본 연구에서는 AGS 위암세포에서 벌사상자 에탄올 추출물(CME)에 대한 세포주기 정지 유도 효과를 확인하고자 하였다. CME 처리에 의한 AGS 위암세포의 증식 억제 유도 효과 및 세포독성 효과를 확인하기 위하여 MTT assay와 LDH release assay를 실시한 결과, 농도 및 시간 의존적으로 세포생존율이 감소하였으며, 농도 의존적인 세포독성 효과를 확인하였다. 또한, CME의 농도가 증가할수록 AGS 위암세포의 형태학적 변화가 관찰되었다. 이러한 세포증식 억제 유도 효과가 세포주기 정지에 의한 것인지 확인하기 위하여 CME를 농도별로 24시간 동안 처리한 후 세포주기를 측정하였다. 그 결과 G1기의 세포가 농도 의존적으로 증가함을 확인하였다. 그리고 CME의 처리가 세포주기와 관련된 단백질에 미치는 영향을 알아보기 위하여 western blot analysis를 실시하여 G1기 세포주기 정지와 관련된 신호 단백질들의 발현 변화를 확인하였다. 그 결과 CME의 처리가 세포 증식과 분열에 중요한 역할을 하는 p-Akt와 p-GSK-$3{\beta}$의 발현을 저해하는 것을 확인하였고, 이에 따라 p53의 발현과 활성이 증가하여 p21의 발현이 증가함을 확인하였다. 또한, p21의 증가에 따른 cyclin E의 발현 감소와 CDK2의 비활성화 상태인 p-CDK(T14), p-CDK(Y15)의 발현 증가를 확인하였다. 이와 같은 CME의 세포주기 억제 유도 효과가 일어나는 신호경로를 확인하기 위하여 LY294002(PI3K/Akt 저해제), BIO(GSK-$3{\beta}$ 저해제), Pifithrin-${\alpha}$(p53 저해제)를 CME와 각각 또는 병행 처리한 후 MTT assay, 세포주기 측정, western blot analysis를 진행하였다. 그 결과 LY294002의 처리는 CME 처리군과 유사하게 세포생존율을 저해시키고 G1기 정지를 유도했으며, 세포주기 단백질을 조절하였다. 또한, GSK-$3{\beta}$와 p53 저해제를 처리하였을 때 CME를 병행 처리했음에도 불구하고 세포증식 억제나 G1기 정지와 같은 항암 효과가 나타나지 않았으며, 관련 신호경로 단백질의 변화도 관찰되지 않았다. 이러한 결과는 CME의 처리가 Akt/GSK-$3{\beta}$/p53 신호경로를 조절하여 cyclin E의 발현을 감소시키고 CDK2의 활성을 억제함으로써 G1기 세포주기 정지를 유도함을 확인하였다.